BRK-B vs RAND
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
RAND exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a completely bearish technical trend (0/100). While the stock trades at a discount to book value (P/B 0.61), this is offset by a catastrophic profit margin of -124.17% and a significant revenue contraction of -39.90% YoY. The high dividend yield of 10.74% appears unsustainable given the lack of earnings growth and negative ROE. Overall, the data suggests a value trap where low valuation metrics are a reflection of deteriorating fundamental health.
Compare Another Pair
Related Comparisons
BRK-B vs RAND: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Rand Capital Corporation (RAND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.